IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against SCYNEXIS, Inc. and Encourages Investors with Losses to Contact the Firm

IRVINE, Calif.--()--Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) (Nasdaq: SCYX). Investors who purchased or otherwise acquired SCYNEXIS shares between May 2, 2014, and March 2, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the May 8, 2017 lead plaintiff deadline.

“[t]he clinical hold decision was issued by the FDA following a review of three mild-to-moderate thrombotic events in healthy volunteers receiving the IV formulation of SCY-078 at the highest doses and highest concentrations in a Phase 1 study.”

If you purchased shares of SCYNEXIS during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

SCYNEXIS disclosed that the U.S. Food and Drug Administration (“FDA”) has issued a hold on clinical trials for the intravenous formulation of the Company’s lead product candidate SCY-078 “until the FDA completes a review of all available pre-clinical and clinical data.” SCYNEXIS explained to shareholders that “[t]he clinical hold decision was issued by the FDA following a review of three mild-to-moderate thrombotic events in healthy volunteers receiving the IV formulation of SCY-078 at the highest doses and highest concentrations in a Phase 1 study.”

When this information was offered to the investing public, SCYNEXIS stock dropped, causing investors harm.

If you wish to learn more about this lawsuit at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Khang & Khang LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

Recent Stories

RSS feed for Khang & Khang LLP

Khang & Khang LLP